Injectable vs. oral letrozole in early breast cancer
Part of Cancer, Skin clinical trials.
This study compares a new injectable form of the drug letrozole with the standard oral pill. It aims to find out if the injection works as well as the pill for women who have already taken letrozole for their early breast cancer and have finished their initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who is postmenopausal (no longer having menstrual periods).
- You have been diagnosed with early stage hormone receptor positive (HR+) breast cancer, either HER2 negative or positive.
- You have completed at least 5 years of endocrine therapy (like letrozole) — or at least 4 years if your doctor says you are low risk — with at least 2 years on letrozole.
- You weigh at least 50 kg (about 110 pounds) and have a body mass index between 19 and 39.
- You have had a mammogram within the last year showing no new cancer, or are willing to have one done before the study starts.
- You are generally in good health and do not have serious medical conditions like heart disease, osteoporosis, or active hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new version of the hormone therapy letrozole (Letrozole SIE) compared to the standard letrozole (Femara®), both given together with a targeted therapy called ribociclib. It is for postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to other parts of the body and has not yet been treated for advanced disease.
This trial tests whether taking letrozole before surgery can help shrink tumors in postmenopausal women with a specific type of early-stage breast cancer that is hormone-receptor-positive, HER2-negative, and has spread to lymph nodes.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
Hear when a new Hormone Receptor Positive Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.